• Home
  • News and Events

News and events

  • Email
  • Help

This section of the website contains the European Medicines Agency's news and press releases, information on meetings and events, public consultations and related information.

For a scrolling feed of all of the new and updated information published on the website, see the what's new page.

Latest news

This month's events

July 2015

M T W T F S S
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31
  • 20/07/2015 - 23/07/2015 : CHMP

    Committee for Medicinal Products for Human Use (CHMP): 20-23 July 2015

    The Committee for Medicinal Products for Human Use (CHMP) is the committee that is responsible for preparing the Agency's opinions on all questions concerning human medicines.

  • 16/07/2015 - 17/07/2015 : CAT

    Committee for Advanced Therapies (CAT): 16-17 July 2015

    The Committee for Advanced Therapies (CAT) is the committee that is responsible for assessing the quality, safety and efficacy of advanced-therapy medicines.

  • 15/07/2015 - 17/07/2015 : PDCO

    Paediatric Committee (PDCO): 15-17 July 2015

  • 14/07/2015 - 15/07/2015 : COMP

    Committee for Orphan Medicinal Products (COMP): 14-15 July 2015

    The Committee for Orphan Medicinal Products (COMP) is the committee that is responsible for reviewing applications for 'orphan medicinal product designation' for medicines intended for the diagnosis, prevention or treatment of rare diseases.

  • 07/07/2015 - 09/07/2015 : CVMP

    Committee for Medicinal Products for Veterinary Use (CVMP): 7-9 July 2015

    The Committee for Medicinal Products for Veterinary Use (CVMP) is the committee that is responsible for preparing the Agency's opinions on all questions concerning veterinary medicines.

  • 06/07/2015 - 07/07/2015 : HMPC

    Committee for Herbal Medicinal Products (HMPC): 6-7 July 2015

    The Committee on Herbal Medicinal Products (HMPC) is the committee that is responsible for preparing the Agency’s opinions on questions relating to herbal medicines.

  • 06/07/2015 - 09/07/2015 : PRAC

    Pharmacovigilance Risk Assessment Committee (PRAC): 6-9 July 2015

    The Pharmacovigilance Risk Assessment Committee (PRAC) is the committee that is responsible for assessing all aspects of the risk management of medicines for human use.

  • 06/07/2015 - 06/07/2015 : EMA

    Workshop on first-line acute promyelocytic leukaemia treatment: European Union cooperative groups and the pharmaceutical industry

    The European Medicines Agency (EMA) is hosting a meeting with European clinical cooperative groups, the pharmaceutical industry and other regulators to discuss first-line treatment of acute promyelocytic leukaemia (APL). The topics addressed will include a historical outlook of APL treatment, recent published trials using arsenic trioxide, guidelines on clinical trials in small populations, experience with the assessment of marketing authorisation applications for rare cancers based on academic trials, benefits to patients of further product development and regulatory submissions. Registration by invitation only.

  • 06/07/2015 - 06/07/2015 : EMA

    Meeting on redacting commercially confidential information (CCI) in clinical reports and anonymising clinical reports for the purpose of publication

    The European Medicines Agency (EMA) is organising a face-to-face meeting on 6 July 2015 at the EMA to allow more detailed discussions on guidance being developed on anonymisation of clinical reports for publication and on redacting commercially confidential information in clinical reports. This meeting follows the webinar held on 24 June which provided an update on the implementation of the policy on the publication of clinical data. Stakeholder organisations have been contacted to nominate experts as participants in this meeting. Places limited. Registration by invitation only. Registration closed.

  • 01/07/2015 - 02/07/2015 : EMA

    Workshop on haemophilia registries

    Independent, disease-based registries are a potential source of valuable safety and efficacy data on products. The European Medicines Agency (EMA) is currently embarking on a strategy for patient registries. This initiative provides an appropriate starting point to consider what regulators need from haemophilia registries. The aim is to get the best capture of data in the European Union (EU) and build on existing expertise in this area. It is proposed to work with stakeholders on this topic, commencing with this EMA workshop. Places limited. Registration open until 01/06/2015.